News GH Research leaps on psychedelic data in depression After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category.
News J&J's Spravato gets another lift with new FDA approval Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.
News EU approves endometrial, lung cancer drugs from GSK and J&J Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.
News J&J files intravesical bladder cancer drug TAR-200 in US Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).
News J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
News J&J says Rybrevant combo has survival edge over Tagrisso Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.